Kymera Therapeutics (KYMR) Profit After Tax Growth (3y) (2022 - 2026)

Kymera Therapeutics (KYMR) Profit After Tax Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.53%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -27.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 70.25%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Kymera Therapeutics 10.84 Bn 10.19 Bn - -19.15%

Historic Data

Download Data
DateValue
Mar 31, 2026 -19.15%
Dec 31, 2025 -44.83%
Sep 30, 2025 -23.48%
Jun 30, 2025 -23.92%
Mar 31, 2025 -21.37%
Dec 31, 2024 -27.79%
Sep 30, 2024 -26.93%
Jun 30, 2024 -19.79%
Mar 31, 2024 -54.86%
Dec 31, 2023 -4.24%
Sep 30, 2023 -84.86%
Jun 30, 2023 -39.87%
Mar 31, 2023 -56.30%
Dec 31, 2022 -37.04%
Sep 30, 2022 -55.58%